IRADIMED CORPORATION to Participate at the 38th Annual Roth Conference
Rhea-AI Summary
IRADIMED CORPORATION (NASDAQ: IRMD) will participate in the 38th Annual Roth Conference. CEO Roger Susi and CFO Jack Glenn will hold one-on-one investor meetings at the Ritz-Carlton, Laguna Niguel, CA, on March 22 and March 24, 2026.
This presentation provides an opportunity for investors to meet senior management and discuss strategy and financial priorities face-to-face.
Positive
- None.
Negative
- None.
News Market Reaction – IRMD
In the Mar 16 session, IRMD gained 2.01%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Earnings & dividend | Positive | +9.6% | Record Q4 and 2025 results with higher dividend and 2026 guidance. |
| Feb 04 | Earnings call notice | Positive | +0.7% | Announcement of Q4 and full-year 2025 results release and call. |
| Dec 08 | Special dividend | Positive | +1.0% | Special $0.50 dividend following strong multi‑quarter revenue growth. |
| Nov 10 | Growth award | Positive | +2.1% | Named to TIME’s America’s Growth Leaders list based on growth metrics. |
| Nov 03 | Earnings beat | Positive | +9.5% | Record Q3 2025 results, raised full‑year guidance and regular dividend. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
IRMD has shown consistently positive price reactions to earnings, dividend, and recognition news, with shares rising after each of the last five reported events.
Over the last several months, IRMD has reported record quarterly and full‑year 2025 results, raised its regular dividend to $0.20 per share, and paid a special $0.50 dividend, all while highlighting strong revenue growth and high margins. The company also gained recognition on TIME’s America’s Growth Leaders list and advanced its next‑generation 3870 pump rollout. Against this backdrop of sustained operational strength and shareholder returns, today’s conference participation update fits into an ongoing investor‑relations and visibility push rather than marking a new financial inflection point.
Key Terms
nasdaq financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 38th Annual Roth Conference.
Iradimed’s CEO, Roger Susi, and CFO, Jack Glenn, will host one-on-one meetings between company management and investors at the 38th Annual Roth Conference, which will be held at the Ritz-Carlton in Laguna Niguel, CA, on March 22 and 24, 2026.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.
We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can cause radio-frequency interference and are dangerous to operate in the presence of the powerful magnet used in an MRI system. Our patented MRidium® MRI-compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, allowing it to operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from the critical care unit to the MRI and back, increasing patient safety through uninterrupted vital-signs monitoring and reducing the time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and an optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI-compatible patient vital signs monitoring system has an easy-to-use design and enables effective communication of patient vital signs to clinicians.
For more information, please visit www.iradimed.com.
Media Contact:
Jack Glenn
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com
